



Nutritional care in motor neurone disease/ 
amyotrophic lateral sclerosis
Assistência nutricional nas doenças do neurônio motor/esclerose lateral amiotrófica
Cristina Cleide dos Santos Salvioni1, Patricia Stanich2, Claudinéa S. Almeida3, Acary Souza Bulle Oliveira4
Motor neuron diseases (MNDs) are a group of neurode-
generative clinical syndromes characterised by neuronal 
death in motor cortex, brainstem and ventral horn of the 
spinal cord. Amyotrophic lateral sclerosis (ALS) is the most 
common of the MNDs, defined by the progressive degenera-
tion of upper and lower motor neurons, and causes atrophy, 
fasciculation, weakness and spasticity1,2. The natural course 
of ALS can be defined as death from respiratory failure3. The 
prevalence rate of ALS currently is 2.7-7.4 per 100,000 inhabi-
tants; the incidence is 1.9 per 100,000 inhabitants4.
The aetiology of ALS is not fully clarified; however, exci-
totoxicity from glutamate neurotransmitter, changes in im-
munity, deficiency of neurotrophic factors, physical traumas, 
persistent viral infections and even environmental factors 
has been suggested as possible causes of the disease5,6. 
During the course of ALS, nutritional status (NS) de-
clines, and is often inadequately treated in clinical practice, 
Although various studies confirm the correlation between de-
crease in body weight and body mass index as negative pre-
dictors of survival7-9. Some factors are inherent to the amend-
ments to the NS and the reduction of food intake in patients 
with it, such as: loss of appetite, dysphagia, dyspnea, depres-
sion and hypermetabolism10-12. Hypermetabolism origin and 
development in ALS have not been thoroughly elucidated; 
50% of these patients, however, present in hypermetabolic 
state11 causing the increased nutritional needs make the nu-
tritional treatment even more complex. 
The disease affects bulbar muscles of patients first, from 
25% to 30%, resulting in progressive dysphagia and leading to 
decrease in food and hydric intake13. The need for modifying 
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ABSTRACT
Patients with amyotrophic lateral sclerosis (ALS) often present changes in nutritional status. Based on weight loss and on difficulty in nutri-
tional management, this study aims to review the different possibilities and to present guidelines concerning nutritional treatment to such 
patients. Diet characteristics, types of treatment and nutritional therapy indicating administration routes and discussing the details of the 
disease are described herein. Nutritional therapy has been a substantial therapeutic resource for ALS development. 
Keywords: nutritional assessment, nutrition, gastrostomy, amyotrophic lateral sclerosis, motor neuron disease.
RESUMO
Pacientes com esclerose lateral amiotrófica (ELA) frequentemente apresentam alteração do estado nutricional. Baseado na perda ponderal 
de peso e na dificuldade no manejo nutricional, o objetivo desse estudo é rever as estratégias de tratamento nutricional para a manutenção 
do estado nutricional desses doentes. Nesse trabalho, descrevem-se as características da dieta, as formas de tratamento e terapia nutricio-
nal com indicação das vias de administração, bem como discuti-se as particularidades da doença. A terapia nutricional tem se mostrado um 
recurso terapêutico primordial atuante na evolução da ELA. 
Palavras-chave: avaliação nutricional, nutrição, gastrostomia, esclerose lateral amiotrófica, doença do neurônio motor.
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diet consistency contributes to reduction of high-value food-
protein energy. In analysis of food intake, found that only one 
of sixteen patients studied presented appropriate recommen-
dations for front intake energy9.
Malnutrition, common with progression of disease, mus-
cle strength and breathing capacity due to weakening as well 
as increase the relative risk of death13,14,15. 
Meet the energy requirements of macro and micronu-
trients, adjust degree of dysphagia brought and indicate 
enteral nutritional therapy at right time have been the sub-
ject9,11,16. Within this context, this present review aims to 
present nutritional treatment strategies for the maintenance 
of NS of ALS patients.
DIAGNOSTIC CRITERIA
The nutritionists working in the Neuromuscular 
Di sor ders Unit, Department of Neurology and Neurosurgery, 
Escola Paulista de Medicina, Universidade Federal de São 
Paulo deve loped the protocol herein.
Based on the El Escorial17, firstly, we guided the patients 
by neurological assessment and diagnostic confirmation; se ­
condly, by assessing the nutrition team.
Nutritional evaluation method
The assessment of nutritional status before the conduct 
adopted and is composed the clinical history, anthropome-
tric measurements, food history and laboratory tests.
Anthropometric parameters
Weight, height, arm circumference (AC), tricipital skin-
fold (TSF), arm muscle circumference (AMC), arm muscle 
area (AMA) and arm fat area (AFA) are the anthropometric 
parameters considered.
The ideal body weight for each individual is defined ac-
cording to the table of Metropolitan Life Insurance Com pany18. 
Such parameter guides nutritional therapy once so me patients 
do not know how to relate their normal weight. The percen­
tage of weight loss (% WL) is determined according to the 
equation: % WL=(normal weight (kg) - cur rent weight (kg))/
normal weight (kg). Where: normal weight=weight reported 
by the patient before the disease onset; current weight=patient 
weight on the assessment date Individuals with % WL from 5% 
to 10% are considered malnou rished; those with % WL over 
10% are considered severely malnourished19.
The stature is measured in meters (m). We estimated the 
stature for patients unable to walk based on the equations 
proposed by Chumlea et al20. 
The anthropometric index adopted to classify the nu-
tritional status is the body mass index (BMI), obtained by 
dividing weight by the square of height and expressed as 
kg/m2. Nutritional status is classified into four categories: 
malnutrition BMI <18.5 for age <60 years and BMI <22 if 
age ≥60 years; eutrophy or normality if 18.5 ≤ BMI <25 if 
age <60 years and 22 ≤ BMI if age <27 ≥60 years; overweight if 
25 ≤ BMI <30 if age <60 years and 27 ≤ BMI <30 if age ≥60 
years; obesity if BMI ≥30 Kg/m2 21,22.
Arm measurements performed are: AC and TSF. Con -
cerning the AC, is expressed in centimeters and measured at 
the midpoint between the acromion process of the scapula 
and the olecranon. We measured the TSF in millimeters by 
using a calliper. From AC and TSF, we obtained AMC, AMA 
and AFA. Considering as reference the work of Frisancho, we 
assessed AC, TSF, AMC, AMA and AFA23.
Food intake assessment
Food anamnesis is evaluated of reminder. Obtaining de-
tailed dietary historyu target the appropriate nutritional in-
tervention through individualized therapy through analysis 
of energy and intake of macro and micronutrients.
Laboratory tests
The analysis of laboratory tests also makes up nutritio­
nal evaluation. When compared to the clinical signs, nutritio-
nal status can vary slowly, showing that biochemical analy-
sis is valid, however, the results should be interpreted with 
caution. The biochemical data requested are: lipid profile, so­
dium, potassium, serum iron, ferritin, transferrin, phospho-
rus, total protein and serum albumin, fraction, and protein 
linked to retinol.
Amyotrophic lateral sclerosis functional rating scale
Every nutritional assessment is applied the assessment 
scale motor and functional skills (amyotrophic lateral sclero-
sis functional rating scale – ALSFRS-R)24. As a tool, ALSFRS-R 
monitors disability progression in ALS patients and consists 
of 12 items that assess the self­sufficiency levels of patients 
in areas involving nutrition, self-care, ambulation, communi-
cation, dyspnea, orthopnea and ventilatory support require-
ment. Each item is classified according to a scale from zero 
to four points. The lower the score, more severe is the disease.
Nutrition intervention 
The identification of nutritional status through diagnos-
tic methods leads to the formulation of a plan to deal with 
each situation individually.
After analysis of medical history, dietary, anthropome-
tric and biochemical data, in addition to the application of 
ALSFRS-scale R is prescribed food plan and held the dietary 
guidance to patient. The frequency of monitoring is carried 
every 3 months. The care process is continuous, so the goals 
are reworked so that the revaluation is determined if there 
have been changes in diagnosis or condition affecting the pa-
tient’s nutritional risk.
Nutritional treatment protocol can be found in the Figure.
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NUTRITIONAL RECOMMENDATIONS AND 
NUTRITIONAL THERAPY  
Dietary Prescription
Nutritional therapy applied to ALS aims to supply the nu-
tritional needs for all stages of disease progression, minimise 
protein catabolism, ensure oral feeding and indicate early nu-
tritional support.
Generally, more fractionation, high-calorie, high-protein, 
normolipidic, high­fibre, nutrient unchanged, adequate wa-
ter supply and ideal consistency against dysphagia are cha-
racteristics of the diet-oriented treatment. 
Energy needs
To estimate energy requirements, the equation of Harris 
and Benedict25 is used with the current weight, including the 
proposed factors, activity and injury, for chronic diseases, 
Long et al26.
Protein
The calculation of protein requirements is based on 
the recommendations of the Brazilian Society of Food and 
Nutrition27, being offered 1.0 g–1.2 g protein/kg in current 
weight/day. Food intake, source of high biological value pro-
tein, should be highlighted, comprising roughly 70% in total 
protein intake per day. 
Carbohydrates
The diet is oriented normoglycidic (50­60% of total ener-
gy intake) and modified to hypoglycemic, specifically for pa-
tients with abnormal oxygen saturation. For these cases, the 
energy supply must be maintained at the expense of lipids, 
with high-fat diets (>35% of total energy intake). 
3.4 Lipids
It is recommended ingesting 25-35% of total energy 
intake, considering ≤7% saturated fatty acids, ≤10% po­
lyunsa turated fatty acids and ≤20% monounsaturated 
fatty acids28.
3.5 Fibres
The fibre intake gradually restricts itself in the course of 
the disease, worsening dysphagia. Cooking food is necessary 
for a suitable consistency limitation, ensuring that its con-
sumption is not excluded from diet.
Adding cereal flour to porridge, orange juice with papaya 
and dried pitted prunes, liquefied food, boiled and mashed 
vegetables and legumes cooked well are preparations easy to 
swallow and help intestinal transit.
When adequate intake of fibres becomes impossible, sup-
plemental fibre with module containing industrialized mix of 
soluble and insoluble fibres is necessary.
According to the age and sex of the individual, 25-38 g of 
dietary fibre intake per day is recommended29.
Water
At times, when dysphagia signals occur, liquid must be 
thickened to reduce the aspiration risk and offer the pro­
per water requirement to patients. The use of industrialised 
thickeners grants a more suitable consistency to liquid, ho -
wever, excessive consumption can worsen constipation. Ge -
latin, with or without flavour, can also be used as a means to 
modify food consistency.
Food with high liquid content, e.g. fruit and vegetable pu-
ree, fruit juice and smoothies assist in hydration and reaching 
the estimated water requirement of 30-40 mL/kg/day30.
Micronutrients
The micronutrient prescription follows the recommen­
dations of dietary intake recommended according to age and 
sex of patients31-34. 
The summary of dietary prescription is in Table.
Figure. Protocol concerning nutritional care and treatment 
adopted for patients with amyotrophic lateral sclerosis or 
motor neurone disease, treated in the Department of Research 
on Neuromuscular Diseases, Paulista School of Medicine.  
São Paulo, 201117.
Nutritional status assessment
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Nutritional therapy 
Nutritional therapy entails early detection of inefficient 
food intake, need for modifying the diet consistency and ear-
ly indication of alternative diet, which includes probes or os-
tomies (gastrostomy or jejunostomy).
Nutritional treatment on dysphagia
The diet­oriented treatment is set up to facilitate swal-
lowing, optimise nutritional intake and lessen aspiration risk. 
The defined food viscosity and texture must be correlated to 
the degree of dysphagia presented, hence changes in con-
sistency and feeding time include: general diet, with more 
time to perform the meal; supervised, aided and bland diet; 
and supervised soft diet with actions to protect swallowing. 
In general, diet there is no restriction upon food consisten-
cy, prescribed for patients without swallowing complaints. 
Bland diet shows low levels of cellulose and connective tis-
sue, softened by cooking or mechanical action. In soft diet 
foods are softened by cooking and liquefied in cream con-
sistency. Patients requiring changes in the food consistency 
should receive nutritional and clinical monitoring, since the 
total daily food offered can be qualitatively and quantitatively 
inadequate to supply the needs of such patients, making sup-
plementation necessary.
Adjusting the diet is indicated to suit the nutritional va-
lue of the diet and ensure energy intake when consuming cer-
tain foods becomes inefficient. For individuals presenting a 
weight loss ≥10% in normal weight or malnutrition is pres­
cribed industrial protein, energy product, included in the die-
tary habits, aiming for values from 100% to 130% of the indi-
vidual dietary recommendations16.
Enteral nutritional therapy
The indication criteria of percutaneous endoscopic gas-
trotomy (PEG) considers clinical monitoring based on the 
indicators for multidisciplinary assessment, which includes: 
nutritional assessment, emphasising the drop in 10% of body 
weight in the last three months; presence of dysphagia; and 
respiratory function assessment, highlighting forced vital ca-
pacity (FVC) measurement for nearly 50% of what was pre-
dicted35. Limitation for PEG placement is observed in pa-
tients with moderate respiratory risk. In such cases, to insert 
radiologic gastrostomy is proposed, whose method resem-
bles PEG, either between complications during and after the 
procedure or in survival of patients36.
The calliper of the gastrostomy tube shown is prefera­
bly 24 Fr to facilitate diet infusion with different viscosities. 
Nutritional therapy can consist of hand-crafted, industriali-
zed or mixed diet and consider social, economic aspects for 
therapy of choice. Complications of enteral nutritional the-
rapy may occur and should be rigorously assessed. Diarrhoea 
is common and can cause electrolyte imbalance, worse-
ning the nutritional status of patients. In this wise, the main 
causes are: bacterial contamination, diet hyperosmolarity, 
infusion rate, drug therapy, high­fat diet and low­fibre diet. 
To decrease this condition, it is advisable to administer the 
diet in speed and concentration according to patient tole -
rance, adding soluble fibres and reviewing drug therapy with 
medical staff.
By using a syringe (bolus), the homemade-enteral diet 
administration or gravitational administration can be per-
formed. The indication of the infusion method should be 
based on patient status, type of diet, nutritional needs and 
concomitant oral feeding.
Bolus infusion is to infuse 200-300 mL syringe diet with 20 
mL or 60 mL every three hours, slowly infusing with minimal 
pressure on the syringe plunger. In gravitational administra-
tion, the infusion is free, leaving it flowing by means of the 
equipment, driven only by gravity. It is accomplished by en-
teral feeding bottle or bag and equipment, connected to the 
probe of patient. The bottle is placed on movable support at a 
height above the head of the patient.
Regardless of the administration chosen, the chest of the 
patient must be raised to at least 30° during and after one hour 
the diet infusion, to prevent gastroesophageal reflux and pro-
vide more comfort for patients. The probe should be flushed in 
60 mL medium volume of potable water after the administra-
tion of each diet for cleaning the probe and hydration.
IMPORTANT CLINICAL CHARACTERISTICS
The absence of specific methods for nutritional assess-
ment of ALS patients shows the need to integrate clinical 
Table. Nutritional evaluation and dietary guidance.
Nutritional assessment Dietary guidance
Body mass index Largest fractionation Short interval between meals
Arm circumference High caloric Harris and Bennedict25 +activity factor + injury factor
Tricipital skinfold Adequate carbohydrates 50-60% total calories
Arm muscle circumference High protein 1,0 a 1,2 g/kg per day
Arm muscle area Appropriate in lipidis 25-35% total calories
Percentage of weight loss High-fiber 25-38 g per day
Laboratory tests Vitamins and minerals Recommended dietary allowance
Exames laboratoriais Water 30-40 ml/kg per day
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history, anthropometric measurements, food history and 
la boratory tests for classification of nutritional status and 
monitoring of adopted. The BMI, adopted as one of the in-
dicators of nutritional status in our service, has often been 
used7,12,37. The reduction of one (1) kg/m2 from the normal 
weight would be associated with a 20% mortality risk7.
For more precise information on body composition, an -
thropometry of skinfold measures with arm and circles has 
proven to be a valuable tool for identification of malnutri-
tion. In comparative analysis of nutritional status assess-
ment between electrical bioimpedance and anthropome-
try significant differences between the methods, in which 
anthropometric measures per se would be enough to body 
composition analysis, were not observed16,38. An thropometry 
can perhaps reflect both the nutritional status and the loss of 
motor neurons. Both situations, however, are liable to be in-
fluenced and may contribute to disease progression37.
The execution of food recall puts patients in touch with 
the measurement of appetite, food exclusion, food intake, 
quantities ingested, mealtimes and intervals between meals. 
The advantages to use would be the easy, low cost and when 
carried out in series provide estimates of usual intake39.
The decrease in food intake by loss of appetite, dysphagia, 
weakness, dyspnea, decline in ability to self-care and depres-
sion37 that culminates in nutritional status depletion brings 
the need to rescue or preserve the individual’s pleasure in 
ea ting with harmonic presentation plates in color, texture, 
consistency and temperature, in order to increase its pala-
tability. Food habits and preferences, socioeconomic status 
and any environmental factors connected to food must be 
considered to achieve nutritional goals.
The equation of Harris and Benedict25 with  factors for 
calculation of energy needs26 is suggested as a replacement in 
cases where indirect calorimetry is impossible40. Despite the 
discrepancies in the current literature and the lack of know-
ledge on the actual energy requirements of these patients, 
one can assume that continuously assessing food intake, 
weight gain or weight loss and body composition may help to 
treat and individualise energy requirements. It is worth men-
tioning that reductions equal to or greater than usual at mo-
ment weight 5% diagnosis increase at twice the risk of death 
when compared to patients with stable or loss weight less 
than 5%, which reinforces the concept of dont induce weight 
loss in ALS even in cases of overweight.
Hyperproteic diet oriented, with 1.0 to 1.2 g protein/kg/day, 
aims to minimize protein catabolism. In cases of ina dequate 
dietary intake protein modulation is indicated, ho wever, it 
should be pointed out that supplementation with branched 
chain amino acids (l-Leucine, l-valine, l-isoleucine) is contra-
indicated in ALS treatment. Double-blind study investigating 
the effect of branched­chain amino acids was interrupted due 
to mortality and decline in forced vital capacity of patients of 
group under tratament41. Concerning supplementation with 
carnitine and creatine, there were no human studies with 
clear evidence42. 
The distribution of total caloric value carbohydrates of 
diet is normoglycidic (50­60% of total energy intake). The 
need for modifying food consistency leads individual to opt 
for foods associated with greater comfort in time to swal-
low that, generally speaking, are more rich in carbohydrates 
which, in some cases, to the worsening of constipation, com-
mon disorder in these patients as a result of involvement 
of abdominal and pelvic muscles, combined with physical 
inac tivity, drug treatment and low intake of fibres43. The ex-
cessive consumption of carbohydrates can also collaborate 
with decrease in insulin and glucose intolerance has found 
in ALS patients44. Neurodegenerative diseases can cause 
neu roendocrine dysfunction that can influence progression 
of neurodegenerative process45. It is not uncommon to ob-
serve abrupt elevation on lipid profile. Even in these cases, 
the diet is maintained. Furthermore, with the limitation pe-
riod between 25-35% of total energy intake, and nutritional 
recommendations dont involve replacing dairy products by 
skimmed and whole decrease in consumption of food of ani-
mal origin. Dupuis et al46 observed that dyslipidemia plays a 
protective factor for disease progression over 12 months in 
the survival of such patients. Suggested treatments to control 
dyslipidemia may meddle in ALS progression.
Some patients adopt alternative treatments through self-
medication with micronutrients, especially because the ac-
cumulation of free radicals and oxidative stress have been 
proposed as factors that contribute to progression of disease. 
A systematic review selected all randomised or quasi-ran-
domised studies controlled in treatment with an tioxidants 
in ALS, i.e. Cochrane Neuromuscular Disease Group Trials 
re gister (August 2005), MEDLINE ( from January 1996 to 
August 2005), EMBASE ( from January 1980 to August 2005), 
showed insufficient evidence for the efficacy of using antioxi-
dants to treat such patients. Although there is not substantial 
evidence from clinical trials to support the clinical use of an-
tioxidants, there is no contraindication47.
Initial treatment of dysphagia in ALS patients is based 
on changes in consistency, viscosity, temperature and pre-
sentation of food, fractionation and action to facilitate and 
protect48. Nutritional therapy adopted early can prevent the 
depletion of physical stocks, in reducing the body fat lean 
body mass loss inherent to disease. In cases where there is 
intense weight loss, dysphagia and FVC with values close to 
50% predite is considered an enteral nutrition35. In ALS, the 
indication of PEG is the sovereign comparing to other forms 
to access digestive tract for nutrition9,49,50; moreover, it is an 
alternative to administrate fluids and medicines with oral 
feeding, when possible.
The caliber of PEG, preferably 24 french, collaborates with 
management of diet in different viscosities making it possible 
diet. The traditional diet is indicated for patients in monitoring, 
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more by economical aspect than nutritio nal quality of the pre -
paration. In any case, as these patients usually do not pre sent 
digestive or absorptive disorders, using nutrients in its intact 
form (as with fresh food) brings no inconvenience49.
FINAL CONSIDERATIONS
Patients with ALS have presented risk to nutritional status. 
Thus, we highlight how important is the need for early and sys-
tematic nutritional intervention for these pa tients, considering:
1.  Maintaining nutritional status, since the nutritional as-
pect is a prognostic factor for survival in these patients.
2.  Performing anthropometric assessment and contempla-
ting food intake periodically.
3.  Individualising energy requirements during the course of 
the disease.
4.  Ensuring the maintenance of oral feeding without risk of 
bronchoaspiration with change in consistency.
5.  Minimising protein catabolism with the appropriate sup-
ply of macronutrients and micronutrients.
6.  Indicating early nutritional therapy to improve quality of life.
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